Digital Therapeutics for People Living with Moderate to Severe Depression

Dennis Urbaniak, Executive Vice President of Digital Therapeutics at Orexo, a pharmaceutical and digital therapeutics company that addresses the unmet needs in the mental health and substance use space, discusses Deprexis ®, a fully automated digital therapy to help manage symptoms of chronic or recurrent depression or depressive disorders for patients aged 18 and older. Deprexis ®, which is supported by artificial intelligence to tailor delivery based on patients’ progress and specific needs, is software that successfully provides cognitive behavioral therapy (CBT)-based content and other effective psychotherapeutic-based techniques against depression. 

Dennis Urbaniak, Executive Vice President Digital Therapeutics, Orexo, leads Orexo’s digital therapeutics business, initially through the US commercialization of three digital therapies, Deprexis (major depressive disorder and chronic depression), vorvida (problematic drinking), and modia (opioid use disorder) recently licensed from GAIA AG. He also contributes to Orexo’s business development activities, particularly in the search for complementary digital therapeutics opportunities. Dennis brings 25+ years of driving patient and commercial successes in Life Sciences, prior to Orexo he was the Chief Digital Officer, Havas Health & You, Chief Executive Officer, Havas Health Plus.  Prior to Havas Health & You, Managing Director Accenture Digital Life Sciences Analytics and Janssen Client Account Lead. Before joining Accenture, twenty years at Sanofi in various sales and marketing roles.